GlassScriptPhysician profile
James L Baker
NPI 1477530301
$17,527.61
in general payments reported to CMS, 2019-2025
36 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,265 · 2020: $2,335 · 2021: $2,330 · 2022: $2,173 · 2023: $2,413 · 2024: $2,359 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,424.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,348.43 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $2,422.63 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Allergan, INC. | $2,054.00 | 2019 | |
| Janssen Biotech, INC. | $1,657.78 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $1,609.14 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,244.12 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $969.29 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $555.11 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $491.31 | 2019-2024 | Taltz |
| Pfizer INC. | $413.24 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $270.46 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $234.99 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $194.39 | 2021-2023 | Lupkynis |
| Genzyme Corporation | $156.31 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.98 | 2023-2024 | Cyltezo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $124.92 | 2019 | |
| Alexion Pharmaceuticals, INC. | $108.23 | 2019-2025 | Strensiq |
| Kiniksa Pharmaceuticals, LTD. | $64.09 | 2023 | Arcalyst |
| Sobi, INC | $59.08 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $58.01 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $56.81 | 2019 | |
| Genentech USA, INC. | $52.98 | 2019-2025 | Actemra |
| Kiniksa Pharmaceuticals International, Plc | $44.36 | 2024 | Arcalyst |
| Organon LLC | $40.83 | 2022-2025 | Hadlima, Renflexis |
| Mylan Institutional INC. | $18.03 | 2023 | Hulio |
| Hospira, INC. | $17.45 | 2021 | |
| Gilead Sciences, INC. | $17.10 | 2020 | |
| Ani Pharmaceuticals, INC. | $16.79 | 2023 | Purified Cortrophin Gel |
| Grifols USA, LLC | $16.57 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $15.55 | 2023 | Opsumit, Uptravi |
| Teva Pharmaceuticals USA, INC. | $14.46 | 2023 | Truxima |
| Horizon Therapeutics Plc | $14.01 | 2019 | |
| Kyowa Kirin, INC. | $13.65 | 2024 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $12.97 | 2022 | |
| Merck Sharp & Dohme LLC | $12.54 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.